Seeking Alpha

BioCryst (BCRX +7.5%) is up after terminating its merger agreement with private Presidio...

BioCryst (BCRX +7.5%) is up after terminating its merger agreement with private Presidio Pharmaceuticals, which was contingent on BioCryst securing $60M in financing. However, shares are well off their morning highs. BioCryst had agreed to buy Presidio in an all-stock deal once valued at $101M, but its shares had been cut in more than half since then thanks to a withdrawn application for a hepatitis drug, and the ending of trials for a flu drug. SA's PropThink expects BioCryst to remain on the hunt for fresh capital.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector